Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking semaglutide and levothyroxine together is a question that comes up regularly in clinical practice, and the short answer is that the two medicines can generally be used at the same time — but the interaction is real and worth understanding. Semaglutide slows gastric emptying, which can reduce and delay the absorption of oral medicines taken around the same time, including levothyroxine. Levothyroxine is already one of the most absorption-sensitive medicines in use: it is a prescription-only thyroid hormone with a notoriously narrow therapeutic window, meaning even small shifts in how much reaches your bloodstream can affect thyroid function tests and how you feel. Anyone taking both medicines should have their thyroid function monitored, and their prescribers should know about both. Neither medicine makes the other unsafe in principle, but the combination needs clinical oversight — the NHS semaglutide medicines page advises that slowed gastric emptying may affect the absorption of other oral drugs, and this is exactly the mechanism relevant here.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works partly by slowing the rate at which the stomach empties its contents into the small intestine. This is useful for weight management (it prolongs the feeling of fullness) but it also means that anything taken orally sits in the stomach longer before reaching the absorptive surface of the gut. For most medicines, this shifts the timing of absorption without dramatically changing the total amount absorbed. Levothyroxine is a different case. It is absorbed primarily in the small intestine, and the conditions around that absorption are unusually important: taking it with food, coffee, calcium, iron or certain other medicines can meaningfully reduce how much gets through. A medicine that slows gastric emptying adds another variable into that already finely balanced picture. The BNF entry for semaglutide notes that delayed gastric emptying may influence the absorption of concomitant oral medicines, and levothyroxine sits squarely in that category. The practical consequence is not that the combination is contraindicated, it is that thyroid function should be monitored after starting or adjusting semaglutide, because the effective levothyroxine dose may shift even without any change to the levothyroxine prescription itself.
A question our prescribers hear most weeks is whether someone already stable on levothyroxine needs to stop it, change it, or take it at a completely different time of day before starting semaglutide. The honest answer from current guidance is nuanced. There is no UK regulatory contraindication between the two medicines, and no published randomised trial has specifically tested this combination in a way that produces a definitive dosing protocol. What exists is pharmacokinetic reasoning (sound, well-established reasoning) alongside clinical consensus that thyroid function tests should be checked after semaglutide is initiated or after any dose increase. If you are being assessed for Wegovy or oral semaglutide and you take levothyroxine, the right step is to declare both medicines during your consultation. A prescriber who knows your full medicine list can flag to your GP or endocrinologist that monitoring is warranted. Semaglutide is also subject to ongoing pharmacovigilance as a Black Triangle medicine, which means the evidence base continues to develop; any new interaction signals would be reflected in updated guidance. For a broader picture of medicines that may need attention alongside semaglutide, our page on Wegovy drug interactions covers the fuller list alongside semaglutide's interactions with other drugs.
Standard levothyroxine counselling already recommends taking it on an empty stomach, first thing in the morning, at least 30 minutes before food and other medicines, ideally 60 minutes. That spacing should be maintained, or extended where possible, when starting semaglutide. The weekly injection of semaglutide does not have a fixed daily administration time in the same way, so there is no conflict about which to take when: the levothyroxine timing is unchanged. What does need attention is the monitoring schedule. Thyroid stimulating hormone (TSH) and free T4 are the standard tests; if you have recently started semaglutide and your thyroid symptoms have changed (fatigue, weight changes (beyond the expected effects of treatment), cold intolerance, heart rate changes) that is a reason to contact your GP rather than wait for a routine review. For context on how semaglutide fits into the broader clinical picture of weight management treatment, those details are covered on the treatment overview. People interested in how semaglutide handles temperature and storage (relevant if your levothyroxine is also refrigerated) can find the specifics at semaglutide storage and temperature guidance. If you have questions specific to your own medicine list, the most direct route is a clinical conversation: interactions with Wegovy gives a structured starting point, and you can also look at whether levothyroxine and semaglutide can be taken together for a more focused answer on that pairing.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.